 Phase 1 clinical trial will include groups of 5 patients sequentially treated with: 0.5 x 10ˆ6, 1.0 x 10ˆ6, 2-3 x 10ˆ6 donor Tregkg. Phase 2 clinical trial will include another 5 to 10 patients treated with MTD. 